Understanding how specific proteins are recruited to DNA to control cancer-related gene activity
Official title: Characterizing the RNA-mediated recruitment of histone deacetylases to chromatin
Funded at California Institute of Technology · NIH-11095810 · Data updated 2026-11-12
This study is looking at how certain proteins help guide other proteins that control gene activity to specific parts of DNA, which could lead to better and safer treatments for cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | California Institute of Technology NIH-funded |
| Lab location | 1 site (Pasadena, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $54,538 |
| NIH project number | 5F30CA278005-03 |
| Project ID | NIH-11095810 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with various types of cancer who may benefit from more precise treatment options.
✕Less likely to help
Patients whose cancers are not influenced by histone deacetylases or those who are not eligible for targeted therapies may not receive benefits from this research.
What this research studies
This research investigates the mechanisms by which histone deacetylases (HDACs), proteins that play a crucial role in gene regulation, are recruited to specific regions of DNA. By focusing on the interactions between RNA-binding proteins and long noncoding RNAs, the study aims to uncover how these proteins can precisely target HDACs to certain genes, potentially leading to more effective and safer cancer therapies. The approach involves detailed molecular techniques to analyze these interactions and their implications for gene expression in cancer cells.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted cancer therapies that minimize side effects by specifically inhibiting harmful gene activity.
How similar studies have gone: Previous research has shown promise in targeting specific HDAC isoforms, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
-
California Institute of Technology
Pasadena, United States Active
Researchers
- Principal investigator: Guo, James Kang — California Institute of Technology
- Study coordinator: Guo, James Kang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.